Back to results
US 10,851,373 B2Granted
Antisense nucleic acids
AssigneesNippon Shinyaku Co., Ltd., National Center of Neurology and Psychiatry
InventorsYukiko Enya, Yuichiro Tone, Shin'ichi Takeda, Yoshitsugu Aoki
Life of this patent
Estimating the term…
Abstract
The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.
Claims20
An antisense oligomer of 14 to 32 bases in length, or a pharmaceutically acceptable salt or hydrate thereof, wherein the antisense oligomer comprises connected two unit oligomers, each of which is selected from a nucleotide sequence complementary to a nucleotide sequence consisting of 7 to 16 contiguous bases selected from any one of SEQ ID NOs:
- 3-6 and 143, and wherein the two unit oligomers are not contiguous to each other or do not overlap with each other.
Dependencies are inferred from the claim text.